The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

As Neuphoria Therapeutics considers its options in the wake of the failure of its phase 3 social anxiety program, an ...

Q3 2025 Earnings Call Transcript November 10, 2025 Assertio Holdings, Inc. beats earnings expectations. Reported EPS is ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

Dietitians are not just end-users of AI tools. They can be cocreators, leaders, and subject matter experts on AI projects. In ...

In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in ...

The rapid development and integration of artificial intelligence (AI), including predictive, generative, and emerging agentic ...

Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical ...

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been ...

One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...